Skip to main content

Articles

Page 19 of 38

  1. Triple-negative breast cancer (TNBC) is an aggressive disease that currently lacks effective targeted therapy. NKG2D ligands (NKG2DLs) are expressed on various tumor types and immunosuppressive cells within tu...

    Authors: Yali Han, Wei Xie, De-Gang Song and Daniel J. Powell Jr
    Citation: Journal of Hematology & Oncology 2018 11:92
    Content type: Research Published on:

  3. The original article [1] contains a spelling error in the authorship; the authors would like to note the correct spelling of the second author, Jiajia Xi.

    Authors: Qian Huang, Jiajia Xi, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, Munish Kumar, Zhiyuan Zhou, Ling Li, Zhaoyang Zeng, Ken H. Young, Qing Yi, Mingzhi Zhang and Yong Li
    Citation: Journal of Hematology & Oncology 2018 11:90
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2018 11:58

  4. Colorectal cancer (CRC) arises in a multistep molecular network process, which is from either discrete genetic perturbation or epigenetic dysregulation. The long non-coding RNAs (lncRNAs), emerging as key mole...

    Authors: Yang Li, Changqian Zeng, Jialei Hu, Yue Pan, Yujia Shan, Bing Liu and Li Jia
    Citation: Journal of Hematology & Oncology 2018 11:89
    Content type: Research Published on:

  5. The insulin-like growth factor-2 mRNA-binding protein 1 (IGF2BP1) plays essential roles in embryogenesis and carcinogenesis. IGF2BP1 serves as a post-transcriptional fine-tuner regulating the expression of som...

    Authors: Xinwei Huang, Hong Zhang, Xiaoran Guo, Zongxin Zhu, Haibo Cai and Xiangyang Kong
    Citation: Journal of Hematology & Oncology 2018 11:88
    Content type: Review Published on:

  6. Mantle cell lymphoma (MCL) is an aggressive and incurable lymphoma. Standard of care for younger patients with MCL is induction chemotherapy followed by autologous stem cell transplantation (auto-HCT). Rituxim...

    Authors: Robert W. Chen, Joycelynne M. Palmer, Sarah Tomassetti, Leslie L. Popplewell, Jessica Alluin, Pritsana Chomchan, Auayporn P. Nademanee, Tanya Siddiqi, Ni-Chun Tsai, Lu Chen, Fay Zuo, Rosemarie Abary, Ji-lian Cai, Alex F. Herrera, John J. Rossi, Steven T. Rosen…
    Citation: Journal of Hematology & Oncology 2018 11:87
    Content type: Research Published on:

  7. Preclinical data have shown that ERBB2 activating mutations are responsive to HER2 tyrosine kinase inhibitors. The aim of this study is to characterize the landscape of ERBB2 mutations in solid tumors and the ...

    Authors: Sophie Cousin, Emmanuel Khalifa, Amandine Crombe, Yech’an Laizet, Carlo Lucchesi, Maud Toulmonde, Sylvestre Le Moulec, Céline Auzanneau, Isabelle Soubeyran and Antoine Italiano
    Citation: Journal of Hematology & Oncology 2018 11:86
    Content type: Letter to the Editor Published on:

  8. Inhibition of metastasis of head and neck squamous cell carcinoma (HNSCC) is one of the most important challenges in cancer treatment. Src, a non-receptor tyrosine kinase, has been implicated as a key promoter...

    Authors: Liwei Lang, Chloe Shay, Yuanping Xiong, Parth Thakkar, Ron Chemmalakuzhy, Xuli Wang and Yong Teng
    Citation: Journal of Hematology & Oncology 2018 11:85
    Content type: Research Published on:

  10. Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becomi...

    Authors: Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie and Michael Wang
    Citation: Journal of Hematology & Oncology 2018 11:83
    Content type: Review Published on:

  11. The initiation and progression of hepatocellular carcinoma (HCC) are largely dependent on its local microenvironment. Adipocytes are an important component of hepatic microenvironment in nonalcoholic fatty liv...

    Authors: Shihua Wang, Meiqian Xu, Xiaoxia Li, Xiaodong Su, Xian Xiao, Armand Keating and Robert Chunhua Zhao
    Citation: Journal of Hematology & Oncology 2018 11:82
    Content type: Research Published on:

  14. Ibrutinib is an oral irreversible inhibitor of Bruton’s tyrosine kinase, indicated for the treatment of chronic lymphocytic leukaemia. The drug is generally well tolerated; however, not infrequent side effects...

    Authors: Gianluigi Reda, Bruno Fattizzo, Ramona Cassin, Veronica Mattiello, Tatiana Tonella, Diana Giannarelli, Ferdinando Massari and Agostino Cortelezzi
    Citation: Journal of Hematology & Oncology 2018 11:79
    Content type: Letter to the Editor Published on:

  16. Despite the overwhelming number of investigations on AKT, little is known about lncRNA on AKT regulation, especially in GBM cells.

    Authors: Changhong Liu, Yan Zhang, Xiaoling She, Li Fan, Peiyao Li, Jianbo Feng, Haijuan Fu, Qing Liu, Qiang Liu, Chunhua Zhao, Yingnan Sun and Minghua Wu
    Citation: Journal of Hematology & Oncology 2018 11:77
    Content type: Research Published on:

  19. Epithelial-to-mesenchymal transition (EMT) has, in recent years, emerged as an important tumor cell behavior associated with high metastatic potential and drug resistance. Interestingly, protein SUMOylation an...

    Authors: Nithila A. Joseph, Shiow-Her Chiou, Zoe Lung, Cheng-Lin Yang, Tze-Yi Lin, Hui-Wen Chang, H. Sunny Sun, Sachin Kumar Gupta, Laising Yen, Shulhn-Der Wang and Kuan-Chih Chow
    Citation: Journal of Hematology & Oncology 2018 11:74
    Content type: Research Published on:

  20. The increasing genomic complexity of acute myeloid leukemia (AML), the most common form of acute leukemia, poses a major challenge to its therapy. To identify potent therapeutic targets with the ability to blo...

    Authors: Xiaolan Lian, Yu-Min Lin, Shingo Kozono, Megan K. Herbert, Xin Li, Xiaohong Yuan, Jiangrui Guo, Yafei Guo, Min Tang, Jia Lin, Yiping Huang, Bixin Wang, Chenxi Qiu, Cheng-Yu Tsai, Jane Xie, Ziang Jeff Gao…
    Citation: Journal of Hematology & Oncology 2018 11:73
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:94

  21. Targeting cancer stem cells is critical for suppressing cancer progression and recurrence. Finding novel markers or related pathways could help eradicate or diagnose cancer in clinic.

    Authors: Lufeng Zheng, Chenxi Xiang, Xiaoman Li, Qianqian Guo, Lanlan Gao, Haiwei Ni, Yufeng Xia and Tao Xi
    Citation: Journal of Hematology & Oncology 2018 11:72
    Content type: Research Published on:

  22. Binding of insulin-like growth factor-I (IGF-1) to its receptor (IGF-1R) initiates downstream signals that activate PI3K/Akt/mTOR and MEK/Erk pathways, which stimulate cancer cell proliferation and induce drug...

    Authors: Reham Abdel-Wahab, Gauri R. Varadhachary, Priya R. Bhosale, Xuemei Wang, David R. Fogelman, Rachna T. Shroff, Michael J. Overman, Robert A. Wolff and Milind Javle
    Citation: Journal of Hematology & Oncology 2018 11:71
    Content type: Research Published on:

  23. Chemoresistance to temozolomide (TMZ) is a major challenge in the treatment of glioblastoma (GBM). We previously found that miR-519a functions as a tumor suppressor in glioma by targeting the signal transducer an...

    Authors: Hong Li, Lei Chen, Jun-jie Li, Qiang Zhou, Annie Huang, Wei-wen Liu, Ke Wang, Liang Gao, Song-tao Qi and Yun-tao Lu
    Citation: Journal of Hematology & Oncology 2018 11:70
    Content type: Research Published on:

  24. The international, phase 3 COMPARZ study demonstrated that pazopanib and sunitinib have comparable efficacy as first-line therapy in patients with advanced renal cell carcinoma, but that safety and quality-of-...

    Authors: Jun Guo, Jie Jin, Mototsugu Oya, Hirotsugu Uemura, Shunji Takahashi, Katsunori Tatsugami, Sun Young Rha, Jae-Lyun Lee, Jinsoo Chung, Ho Yeong Lim, Hsi Chin Wu, Yen Hwa Chang, Arun Azad, Ian D. Davis, Marlene J. Carrasco-Alfonso, Bhupinder Nanua…
    Citation: Journal of Hematology & Oncology 2018 11:69
    Content type: Research Published on:

  25. Metastatic melanoma is an aggressive skin cancer with a poor prognosis. Current treatment strategies for high-stage melanoma are based around the use of immunotherapy with immune checkpoint inhibitors such as ...

    Authors: Carmela De Santo, Paul Cheng, Andrew Beggs, Sharon Egan, Alberto Bessudo and Francis Mussai
    Citation: Journal of Hematology & Oncology 2018 11:68
    Content type: Case report Published on:

  26. Multiple myeloma is the second most frequent hematological malignancy in the western world and remains incurable, predominantly due to acquired drug resistance and disease relapse. The highly conserved Wnt sig...

    Authors: Ingrid Spaan, Reinier A. Raymakers, Anja van de Stolpe and Victor Peperzak
    Citation: Journal of Hematology & Oncology 2018 11:67
    Content type: Review Published on:

  27. Multiple myeloma (MM) remains an incurable malignancy despite the recent advancements in its treatment. The protective effects of the niche in which it develops has been well documented; however, little has be...

    Authors: Rachel E. Piddock, Christopher R. Marlein, Amina Abdul-Aziz, Manar S. Shafat, Martin J. Auger, Kristian M. Bowles and Stuart A. Rushworth
    Citation: Journal of Hematology & Oncology 2018 11:66
    Content type: Letter to the Editor Published on:

  28. Disruption of the physiologic balance between cell proliferation and cell death is an important step of cancer development. Increased resistance to apoptosis is a key oncogenic mechanism in several hematologic...

    Authors: Guilherme Fleury Perini, Glaciano Nogueira Ribeiro, Jorge Vaz Pinto Neto, Laura Tojeiro Campos and Nelson Hamerschlak
    Citation: Journal of Hematology & Oncology 2018 11:65
    Content type: Review Published on:

  30. The deeper understanding of non-coding RNAs has recently changed the dogma of molecular biology assuming protein-coding genes as unique functional biological effectors, while non-coding genes as junk material ...

    Authors: Nicola Amodio, Lavinia Raimondi, Giada Juli, Maria Angelica Stamato, Daniele Caracciolo, Pierosandro Tagliaferri and Pierfrancesco Tassone
    Citation: Journal of Hematology & Oncology 2018 11:63
    Content type: Review Published on:

  31. Promotor hypermethylation of CpG islands is common in B cell precursor acute lymphoblastic leukemia (BCP-ALL) with mixed lineage leukemia (MLL) gene rearrangements. Hypomethylating agents (HMA) such as azaciti...

    Authors: C. Roolf, A. Richter, C. Konkolefski, G. Knuebel, A. Sekora, S. Krohn, J. Stenzel, B. J. Krause, B. Vollmar, H. Murua Escobar and C. Junghanss
    Citation: Journal of Hematology & Oncology 2018 11:62
    Content type: Research Published on:

  32. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a highly aggressive hematological malignancy with extremely poor outcome. The median overall survival for adult patients is 9–13 months. Pediatric patien...

    Authors: Weili Sun, Huaying Liu, Young Kim, Nicole Karras, Anna Pawlowska, Debbie Toomey, Wade Kyono, Paul Gaynon, Joseph Rosenthal and Anthony Stein
    Citation: Journal of Hematology & Oncology 2018 11:61
    Content type: Case report Published on:

  33. Chimeric antigen receptor-engineered T (CAR-T) cells have extraordinary effect in treating lymphoblastic leukemia. However, treatment of acute myeloid leukemia (AML) using CAR-T cells remains limited to date. ...

    Authors: Ying Wang, Yingxi Xu, Saisai Li, Jia Liu, Yanyan Xing, Haiyan Xing, Zheng Tian, Kejing Tang, Qing Rao, Min Wang and Jianxiang Wang
    Citation: Journal of Hematology & Oncology 2018 11:60
    Content type: Research Published on:

  35. Indoleamine 2,3-dioxygenase 1 (IDO1) catalyzes the first and rate-limiting step in converting tryptophan to kynurenine. Chimeric antigen receptor (CAR) T cells are T cells with recombinant receptors targeting ...

    Authors: Qian Huang, Jiajia Xia, Lei Wang, Xu Wang, Xiaodong Ma, Qipan Deng, Yong Lu, Munish Kumar, Zhiyuan Zhou, Ling Li, Zhaoyang Zeng, Ken H. Young, Qing Yi, Mingzhi Zhang and Yong Li
    Citation: Journal of Hematology & Oncology 2018 11:58
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2018 11:90

  36. CD30 and programmed cell death protein 1 (PD-1) are two ideal therapeutic targets in classical Hodgkin lymphoma (cHL). The CD30 antibody-drug conjugate (ADC) brentuximab vedotin and the PD-1 antibodies nivolum...

    Authors: Yucai Wang, Grzegorz S. Nowakowski, Michael L. Wang and Stephen M. Ansell
    Citation: Journal of Hematology & Oncology 2018 11:57
    Content type: Review Published on:

  37. The original article [1] contains an error in Fig. 5a whereby the Western blot bands representing CyclinD1 have mistakenly been duplicated over the Western blot bands intended to represent SGK.

    Authors: Man-Qing Cao, A-Bin You, Xiao-Dong Zhu, Wei Zhang, Yuan-Yuan Zhang, Shi-Zhe Zhang, Kei-wei Zhang, Hao Cai, Wen-Kai Shi, Xiao-Long Li, Kang-Shuai Li, Dong-Mei Gao, De-Ning Ma, Bo-Gen Ye, Cheng-Hao Wang, Cheng-Dong Qin…
    Citation: Journal of Hematology & Oncology 2018 11:56
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2018 11:12

  38. Acute myeloid leukemia (AML) is both more common and with more biologically aggressive phenotype in the elderly. Allogenic stem cell transplantation (allo-SCT) is the best treatment option in fit patients. Eit...

    Authors: Nicole Santoro, Myriam Labopin, Federica Giannotti, Gerard Ehninger, Dietger Niederwieser, Arne Brecht, Matthias Stelljes, Nicolaus Kröger, Herman Einsele, Matthias Eder, Michael Hallek, Bertram Glass, Jürgen Finke, Fabio Ciceri, Mohamad Mohty, Annalisa Ruggeri…
    Citation: Journal of Hematology & Oncology 2018 11:55
    Content type: Research Published on:

  40. C-X-C motif ligand 8 (CXCL8), known as a proinflammatory chemokine, exerts multiple effects on the proliferation, invasion, and migration of tumor cells via the autocrine or paracrine manner. Conversely, the h...

    Authors: Qian Liu, Anping Li, Shengnan Yu, Shuang Qin, Na Han, Richard G. Pestell, Xinwei Han and Kongming Wu
    Citation: Journal of Hematology & Oncology 2018 11:53
    Content type: Research Published on:

    The Correction to this article has been published in Journal of Hematology & Oncology 2022 15:175

  41. Long non-coding RNA (lncRNA) expression has been implicated in a range of molecular mechanisms that are central in cancer. However, lncRNA expression has not yet been comprehensively characterized in acute mye...

    Authors: Arvind Singh Mer, Johan Lindberg, Christer Nilsson, Daniel Klevebring, Mei Wang, Henrik Grönberg, Soren Lehmann and Mattias Rantalainen
    Citation: Journal of Hematology & Oncology 2018 11:52
    Content type: Research Published on:

  42. The original article [1] contains an inadvertent error in the following sentence in the Abstract regarding the erroneous description of Ser/Thr kinases as ‘phylogenetically related’:

    Authors: Sabrina Manni, Marilena Carrino and Francesco Piazza
    Citation: Journal of Hematology & Oncology 2018 11:51
    Content type: Correction Published on:

    The original article was published in Journal of Hematology & Oncology 2017 10:157

  43. Hepatocellular carcinoma (HCC) ranks as the sixth most prevalent cancer and the third leading cause of tumor-related death, so it is urgently needed to discover efficient markers and targets for therapy. β-1,3-N-...

    Authors: Tianxiao Yang, Yilin Wang, Wenjuan Dai, Xixi Zheng, Jing Wang, Shushu Song, Lan Fang, Jiangfan Zhou, Weicheng Wu and Jianxin Gu
    Citation: Journal of Hematology & Oncology 2018 11:50
    Content type: Research Published on:

  44. In ASPIRE, carfilzomib, lenalidomide, and dexamethasone (KRd) significantly improved progression-free survival (PFS) and response rates versus lenalidomide and dexamethasone (Rd) in patients with relapsed mult...

    Authors: Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel and Philippe Moreau
    Citation: Journal of Hematology & Oncology 2018 11:49
    Content type: Research Published on:

  45. First identified in 1974, m6A RNA methylation, which serves as a predominant internal modification of RNA in higher eukaryotes, has gained prodigious interest in recent years. Modifications of m6A are dynamic and...

    Authors: Yutian Pan, Pei Ma, Yu Liu, Wei Li and Yongqian Shu
    Citation: Journal of Hematology & Oncology 2018 11:48
    Content type: Review Published on:

  46. Immune checkpoint inhibitors (ICIs) therapy is a novel strategy for cancer treatments in recent years. However, it was observed that most patients treated with ICIs could not get benefit from the therapy, whic...

    Authors: Ming Yi, Shengnan Yu, Shuang Qin, Qian Liu, Hanxiao Xu, Weiheng Zhao, Qian Chu and Kongming Wu
    Citation: Journal of Hematology & Oncology 2018 11:47
    Content type: Review Published on:

  47. Even with recent advances in therapy regimen, multiple myeloma patients commonly develop drug resistance and relapse. The relevance of targeting the PD-1/PD-L1 axis has been demonstrated in pre-clinical models...

    Authors: Rosemarie Tremblay-LeMay, Nasrin Rastgoo and Hong Chang
    Citation: Journal of Hematology & Oncology 2018 11:46
    Content type: Review Published on:

  48. Fibroblasts are crucial mediators of tumor-stroma cross-talk through synthesis and remodeling of the extracellular matrix and production of multiple soluble factors. Nonetheless, little is still known about sp...

    Authors: Francesca Andriani, Maria Teresa Majorini, Miguel Mano, Elena Landoni, Rosalba Miceli, Federica Facchinetti, Mavis Mensah, Enrico Fontanella, Matteo Dugo, Mauro Giacca, Ugo Pastorino, Gabriella Sozzi, Domenico Delia, Luca Roz and Daniele Lecis
    Citation: Journal of Hematology & Oncology 2018 11:45
    Content type: Research Published on:

  49. Chimeric antigen receptors (CARs) presented on T cell surfaces enable redirection of T cell specificity, which has enormous promise in antitumor therapy. However, excessive activity and poor control over such ...

    Authors: Erhao Zhang, Jieyi Gu, Jianpeng Xue, Chenyu Lin, Chen Liu, Mengwei Li, Jingchao Hao, Sarra Setrerrahmane, Xiaowei Chi, Weiyan Qi, Jialiang Hu and Hanmei Xu
    Citation: Journal of Hematology & Oncology 2018 11:44
    Content type: Research Published on:

  50. Mantle cell lymphoma (MCL) is an incurable B cell-derived malignant tumor with a median overall survival of 4–5 years. Mer tyrosine kinase (MerTK) has been reported to be aberrantly expressed in leukemia, mela...

    Authors: Cunzhen Shi, Xiangqun Li, Xiaogan Wang, Ning Ding, Lingyan Ping, Yunfei Shi, Lan Mi, Yumei Lai, Yuqin Song and Jun Zhu
    Citation: Journal of Hematology & Oncology 2018 11:43
    Content type: Research Published on:
JHO logo
Submit manuscript

Follow

Annual Journal Metrics

  • 2022 Citation Impact
    28.5 - 2-year Impact Factor
    23.1 - 5-year Impact Factor
    4.045 - SNIP (Source Normalized Impact per Paper)
    6.046 - SJR (SCImago Journal Rank)

    2023 Speed
    5 days submission to first editorial decision for all manuscripts (Median)
    59 days submission to accept (Median)

    2023 Usage 
    3,173,795 downloads
    2,671 Altmetric mentions

On the blog

Institutional membership

Visit the membership page to check if your institution is a member and learn how you could save on article-processing charges (APCs).

Funding your APC

​​​​​​​Open access funding and policy support by SpringerOpen​​

​​​​We offer a free open access support service to make it easier for you to discover and apply for article-processing charge (APC) funding. Learn more here. 

Journal of Hematology & Oncology

ISSN: 1756-8722

Contact us